ReviewAnnals of internal medicine2018
Clostridioides difficile Infection.
Review in Annals of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative effectiveness of treatments for recurrentFrontiers in pharmacology · 2024Pooled it
- Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.Advances in therapy · 2023Pooled it
- High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients WithFrontiers in cellular and infection microbiology · 2022Trial
- Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI.Antonie van Leeuwenhoek · 2026Article
- Deoxycholate induces proline provision from Escherichia coli to enhance Clostridioides difficile virulence.The ISME journal · 2026Article
- Efficacy of UV-C devices in Clostridioides difficile environmental decontamination in a hospital setting: a before-after study.BMC infectious diseases · 2026Article
- Diagnostic challenges and treatment approaches forFrontiers in microbiology · 2026Review
- Clinical and molecular epidemiology ofFrontiers in microbiology · 2026Article
- Comparative genomic analysis of Clostridioides difficile strains in Mexico: insights into virulence and resistance.Access microbiology · 2026Article
- Global burden and trends of theAnnals of medicine · 2025Observational
- AF6 regulates intestinal IgA via crosstalk between intestinal epithelial cells and immune cells in inflammatory bowel disease.iScience · 2025Article
- Clostridioides difficile meets the adenosine system: the art of manipulating host homeostasis.Journal of biomedical science · 2025Review
- Article
- Evaluation of the Efficacy of UV-C Radiation in EliminatingMicroorganisms · 2025Article
- The Global Burden ofInfectious disease reports · 2025Review
- Characterization of heparin interactions with Clostridioides difficile toxins and its potential as anti-CDI therapeutics.Carbohydrate polymers · 2025Article
- Bifidobacterium breve synergizes with Akkermansia muciniphila and Bacteroides ovatus to antagonize Clostridioides difficile.The ISME journal · 2025Article
- Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review.Infection and drug resistance · 2025Review
- Clostridioides difficile infection in Saudi Arabia: Prevalence, risk factors, and outcomes in a tertiary hospital setting.PloS one · 2025Article
- Diabetes Mellitus and the Risk and Outcomes ofInfection and drug resistance · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clostridioides difficile (formerly Clostridium difficile) infection is the most frequently identified health care-associated infection in the United States. C difficile has also emerged as a cause of community-associated diarrhea, resulting in increased incidence of community-associated infection. Clinical illness ranges in severity from mild diarrhea to fulminant colitis and death. Appropriate management of infection requires understanding of the various diagnostic assays and therapeutic options as well as relevant measures to infection prevention. This article provides updated recommendations regarding the prevention, diagnosis, and treatment of incident and recurrent C difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.